<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zorzou, M.P.</style></author><author><style face="normal" font="default" size="100%">Efstathiou, E.</style></author><author><style face="normal" font="default" size="100%">Galani, E.</style></author><author><style face="normal" font="default" size="100%">Bozas, G.</style></author><author><style face="normal" font="default" size="100%">Kastritis, E.</style></author><author><style face="normal" font="default" size="100%">Papadimitriou, C.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author><author><style face="normal" font="default" size="100%">Bamias, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Carboplatin hypersensitivity reactions: A single institution experience</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Chemotherapy</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Carboplatin</style></keyword><keyword><style  face="normal" font="default" size="100%">Hypersensitivity</style></keyword><keyword><style  face="normal" font="default" size="100%">Ovarian cancer</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2005</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2005</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-16244367765&amp;partnerID=40&amp;md5=20c4175b90b08e64af6b85a4c3bfc445</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">17</style></volume><pages><style face="normal" font="default" size="100%">104 - 110</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Carboplatin-related hypersensitivity reactions, frequently encountered in the heavily pretreated subpopulation of patients with gynecologic malignancies, can be severe and even potentially lethal - precluding these patients from an effective salvage treatment. We describe our experience in the management of such reactions and the application of a pretreatment protocol with corticosteroids, antihistamines and a slow infusion rate in order to safely re-administer carboplatin to the above patients. From 1998 to 2004, twenty patients developed an allergic reaction to carboplatin. Sixteen of them (80%) suffered from ovarian cancer. Upon resolution of the acute reaction, thirteen patients were pretreated according to our protocol and were re-exposed to carboplatin. Fifteen patients experienced the reaction during second-line carboplatin-based treatment and 5 patients after 3 or more regimens. Fifteen of the reactions (75%) were severe. Thirteen patients were re-treated with carboplatin after the application of our protocol, all of them successfully, even though 10 patients (77%) experienced minor symptoms during subsequent courses. On the contrary, only one of the 6 patients who were re-treated without the application of the protocol was able to receive further platinum-based treatment. In conclusion, pretreatment with corticosteroids, antihistamines and a slower infusion rate may make re-treatment possible in patients having experienced hypersensitivity to carboplatin. © E.S.I.F.T. srl - Firenze.</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><notes><style face="normal" font="default" size="100%">Cited By :11Export Date: 21 February 2017</style></notes></record></records></xml>